NXTMS Nexstim Ltd

Nexstim Receives an NBS System Order from a Hospital in the Middle East

Nexstim Receives an NBS System Order from a Hospital in the Middle East

Press release, Helsinki, 27 October 2021 at 9 AM (EEST)

Nexstim Receives an NBS System Order from a Hospital in the Middle East

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces having received an NBS system order from a hospital in the Middle East.

Nexstim’s NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. This specific NBS system also includes the software of an NBT® system, allowing the system to also be used for therapeutic treatments.

Mikko Karvinen, CEO of Nexstim commented: “Even though our presence is the strongest in the North American and European markets, operating in markets such as the Middle East is important for us. We are happy to see internationally occurring interest in our systems that enable both diagnostic and therapeutic applications. At Nexstim, we work hard to bring our technology available for as many people as possible; offering solutions to the global challenge of how to effectively diagnose and treat brain diseases and disorders.

Further information is available on the website or by contacting:

Mikko Karvinen, CEO

1

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit

Attachment



EN
27/10/2021

Underlying

NXTMSNexstim Ltd

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nexstim Ltd

 PRESS RELEASE
Free
NXTMS NEXSTIM LTD

Nexstim Receives NBS System 5 Order from European Customer

Nexstim Receives NBS System 5 Order from European Customer Press release, Helsinki, 2 October 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from an existing customer. Nexstim’s NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for non-invasive mapping of the primary motor cortex of the brain. The system provides information that may be used in pre-procedural planning. In addition to the diagnostic features, this specific system also includes t...

October 2, 2024 1 EN
 PRESS RELEASE
Free
NXTMS NEXSTIM LTD

Nexstim Receives Order for NBS System 5 in Finland

Nexstim Receives Order for NBS System 5 in Finland Press release, Helsinki, 27 September 2024 at 10 AM (EEST) Nexstim Receives Order for NBS System 5 in Finland Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received order from a Finnish hospital for an NBS System 5. The customer is new to Nexstim. The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The system provides information that may be used in the assessment of the primary motor cortex for pre-procedural planning. This sp...

September 27, 2024 1 EN
 PRESS RELEASE
Free
NXTMS NEXSTIM LTD

New European Customer Orders Nexstim NBS System 5

New European Customer Orders Nexstim NBS System 5 Press release, Helsinki, 3 September 2024 at 9 AM (EEST) New European Customer Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a new European customer through a distributor. The Nexstim Navigated Brain Stimulation (NBS) System 5 is the only FDA-cleared and CE-marked navigated TMS (Transcranial Magnetic Stimulation) system for pre-operative mapping of the motor and speech cortices of the brain. Mikko Karvinen, CEO of Nexstim, comments: “Our state-of-the-art techno...

September 3, 2024 1 EN
 PRESS RELEASE
Free
NXTMS NEXSTIM LTD

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED)

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED) Company announcement, Helsinki, August 16, 2024 at 9 am (EEST) NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED) NEXSTIM CONTINUED TO GROW AND IMPROVED ITS PROFITABILITY IN THE FIRST HALF OF THE YEAR The figures in parentheses refer to the previous year’s comparative period, unless otherwise stated. January–June 2024 in brief The company’s net sales were EUR 3.2 million (2.5), with an increase of 26.9 %Net sales growth adjusted for currency exchange rates was 26.8 %System sales were EUR 1.2 million (1.1...

August 16, 2024 1 EN
 PRESS RELEASE
Free
NXTMS NEXSTIM LTD

Notice of Nexstim Plc’s Half-Year Report H1 2024

Notice of Nexstim Plc’s Half-Year Report H1 2024 Press release, Helsinki, 13 August 2024 at 3 PM (EEST) Notice of Nexstim Plc’s Half-Year Report H1 2024 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") will publish its half-yearly report for the six months ended 30 June 2024 on Friday 16 August 2024 at approximately 9:00 am Finnish time. The company will hold two live webinars for media, investors, and analysts on Friday 16 August 2024. CEO Mikko Karvinen and CFO Joonas Juokslahti will present the financial and operational results followed by a Q&A session. The first live webinar will b...

August 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch